This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Alzheimer’s disease patients with cognitive impairment or dementia who were referred for amyloid PETscans had fewer hospitalizations compared with a matched control group, according to a study published October 9 in JAMA Neurology. The percentage of patients impacted was small – just 4.5%
The finding suggests that PET imaging of translocator protein (TSPO) in the brain can serve as a biomarker for evaluating patients whose disease progresses despite treatment, noted lead author Tarun Singhal, MD, of Brigham and Women’s Hospital and colleagues. Image courtesy of Clinical Nuclear Medicine.
A group in France has offered an explanation for long COVID brain fog, with the concept based on a visual brain pattern they discovered on patient PETscans, according to a study published October 13 in Medical Hypotheses. “We A) PETscan of a healthy subject. (B) B) PETscan of a long COVID patient.
Chinese clinicians have provided evidence in a “real-world study” that shows amyloid PET imaging is effective for diagnosing and managing patients with Alzheimer’s disease, according to a study published February 8 in Alzheimer’s and Dementia. The clinical utility of amyloid PETscans has been systematically studied in many other countries.
The finding could help explain why Alzheimers disease predominates in women almost twofold over men, noted lead author Gillian Coughlan, PhD, a neurologist at Massachusetts General Hospital in Boston, and colleagues. The group analyzed flortaucipir (Tauvid, Avid Pharmaceuticals) PETscans acquired over a 3.5-year
Early brain accumulation of amyloid plaque on PETscans is associated with emerging depressive symptoms in cognitively unimpaired older adults, according to a study published August 29 in JAMA Network Open. The mean follow-up period was 8.6 The full study is available here.
FAPI-PET imaging could emerge as a new tool for assessing patients with single pulmonary tumors, especially in those with negative results on other scans, according to a study published April 11 in the Journal of Nuclear Medicine. FAPI-PET either confirmed or ruled out the disease in all cases, the group found. “Our
The findings were published in Clinical Nuclear Medicine. The newly published study involved performing PETscans on 22 people with MS and eight healthy controls. Those being treated with low-efficacy treatments had more abnormalities on their PETscans, suggesting more microglial cell activation.
In small studies, F-18 PSMA-1007 PET/CT has shown promise as a more accurate approach based on its ability to reveal prostate-specific membrane antigen (PSMA) on the surface of cancer cells. In this phase II clinical trial, the researchers sought to evaluate the approach further.
F-18 FDG-PET is an established approach for diagnosing inflammation based on its ability to visualize increased cellular glucose metabolism, and the researchers hypothesized that it could be useful in patients with neurosarcoidosis. In all three cases, gadolinium-enhanced MRI scans did not show abnormalities.
To address this limitation, we have recently developed a PET camera equipped with a free-moving function that enables imaging during head motion,” wrote lead author Takafumi Sugi, MD, of Hamamatsu City Rehabilitation Hospital in Shizuoka, Japan, and colleagues. Image courtesy of Scientific Reports. The full study can be found here.
PETscans typically used for diagnosing prostate cancer may have value in detecting inflammatory bowel disease (IBD), according to a case series published December 8 in Clinical and Experimental Gastroenterology. He was admitted to the hospital. Image courtesy of Clinical and Experimental Gastroenterology.
Martha Koperwhats, Texas Children's Hospital 2. Enrico Perez, Columbia Presbyterian-Cornell University Hospitals BEST RADIOLOGIST TRAINING PROGRAM 1. Mayo Clinic, Jacksonville, FL MOST SIGNIFICANT NEWS EVENT IN RADIOLOGY 1. Increased use of medical imaging by other specialties (turf battles) HOTTEST CLINICAL PROCEDURE 1.
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since the U.S. please insert video here.
Centers for Medicare and Medicaid Services (CMS) has announced key changes to reimbursement that make advanced imaging more accessible, lifting its one-scan-per-patient restriction in 2023 and unbundling payment for high-cost diagnostic radiopharmaceuticals in 2024. Facilities wishing to appear on this list can fill out this brief survey.
This study defined an EOAD-signature MRI biomarker using data from a well-characterized discovery sample from Massachusetts General Hospital (MGH) and tested the hypothesis that it can be reproducible in a large validation sample of participants with EOAD. What Are the Clinical Implications?
CR and CNR demonstrated using clinical data with inserted lesions of known size, location, and contrast. Quantitation accuracy demonstrated using clinical data with inserted lesions of known size, location, and contrast (ground truth). Since there is no “typical” hospital and many variables exist, i.e. hospital size, case mix, etc.
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since the U.S.
tesla MRI AI body composition analysis Cardiac PET Cryo/thermoablation CT colonography Genicular artery embolization Hyperpolarized xenon-129 MRI PET/MRI Photon-counting CT Radiomics Theranostics Whole-body MRI screening Image of the Year 3D PET/MR image.
PETscans show that individuals with mothers with a history of memory impairment had higher levels of brain-amyloid plaque associated with Alzheimer’s disease (AD), according to a study published June 17 in JAMA Neurology. Data included participant-reported parental history and baseline F-18 florbetapir ( Amyvid ) PETscans.
PET has provided the first neuroimaging evidence that music affects the brains opioid receptor system, according to researchers in Finland. Unraveling the molecular neural basis of musical hedonia is crucial for understanding the universal human affinity towards music, the group wrote.
A group at Kyushu University in Fukuoka, Japan, found that right ventricular myocardial strain ratio (RVMSR) measurements on N-13 ammonia PET images predicted cardiovascular events and suggested the approach can be used to identify patients who would benefit from clinical interventions.
Reimbursement barriers Unfortunately, until recently, there were significant barriers to receiving amyloid PET imaging in some regions. Centers for Medicare and Medicaid Services (CMS), for example, did not cover amyloid PETscans outside of clinical trials for Medicare beneficiaries and only covered one scan per patient’s lifetime.
The performance improved on the Brock score, a test currently used in clinic, which scored 0.672. The new model also performed comparably to the Herder score, another test currently used in clinic, which had an AUC of 0.83. size, location, spiculation status), but also includes PETscan findings.
Centers for Medicare and Medicaid Services (CMS) has announced key changes to reimbursement that make advanced imaging more accessible, lifting its one-scan-per-patient restriction in 2023 and unbundling payment for high-cost diagnostic radiopharmaceuticals in 2024. Facilities wishing to appear on this list can fill out this brief survey.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content